Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Acadia Healthcare operates 250+ behavioral health facilities across the US and UK, providing inpatient psychiatric care, residential treatment, and outpatient services for mental health and substance abuse disorders. The company serves a fragmented $40B+ behavioral health market with structural tailwinds from rising mental health awareness, opioid epidemic treatment demand, and chronic provider shortages. Stock performance is driven by facility utilization rates, reimbursement dynamics with commercial and government payers, and regulatory compliance in a highly scrutinized sector.
Acadia generates revenue primarily through per-diem reimbursement from commercial insurers (50-55% of revenue), Medicare/Medicaid (40-45%), and self-pay patients. Pricing power varies by payer mix and geography, with commercial rates typically 2-3x government rates. Competitive advantages include scale-driven operational efficiency, specialized clinical expertise in high-acuity behavioral health, and geographic density in key markets that creates referral networks with hospitals and physicians. The business benefits from high barriers to entry (CON requirements in many states, specialized staffing, regulatory complexity) and structural demand growth from deinstitutionalization trends and mental health parity laws.
Same-facility revenue growth and patient days - reflects core demand trends and pricing power across existing footprint
Labor cost inflation and staffing ratios - contract labor and wage pressures have been primary margin headwinds, with staffing costs representing 50%+ of revenue
Regulatory investigations and compliance issues - DOJ inquiries, state licensing actions, and quality-of-care allegations create significant headline risk
Payer mix shifts between commercial and government - commercial rates are 2-3x higher, so shifts materially impact margins
De novo facility openings and M&A activity - growth capital deployment and integration execution drive long-term earnings trajectory
Regulatory and compliance risk - behavioral health facilities face intense scrutiny from CMS, state licensing boards, and DOJ regarding patient safety, billing practices, and quality of care. Historical investigations have resulted in facility closures, fines, and reputational damage that pressures admissions across the portfolio.
Labor market structural shortage - psychiatric nurses, therapists, and specialized clinicians are in chronic short supply, forcing reliance on expensive contract labor and limiting capacity expansion. Wage inflation in healthcare has structurally compressed margins 300-500bps industry-wide since 2020.
Reimbursement pressure - Government payers (40-45% of revenue) face budget constraints, and commercial insurers increasingly use managed care and utilization review to limit inpatient stays. Shift toward value-based care and outpatient alternatives threatens traditional inpatient revenue models.
Fragmented competition from non-profit hospitals expanding behavioral health units, regional chains, and private equity-backed competitors (Springstone, Acadia's former peer now private). Market share gains require capital-intensive facility additions in a supply-constrained environment.
Telehealth and outpatient substitution - virtual behavioral health platforms and intensive outpatient programs are gaining payer and patient acceptance, potentially reducing demand for high-cost inpatient stays that drive Acadia's profitability.
High leverage with 1.36x debt/equity and negative FCF of -$400M creates refinancing risk, especially with $600M annual capex needs. Covenant compliance and liquidity management are critical as EBITDA has been pressured by labor costs and one-time charges.
Negative net margin of -33.3% (TTM) reflects significant one-time charges, restructuring costs, or asset impairments. While adjusted EBITDA is likely positive, the GAAP losses indicate earnings quality concerns and potential for further write-downs if facility performance deteriorates.
low-to-moderate - Behavioral health demand is relatively recession-resistant as mental health crises and substance abuse often increase during economic stress. However, commercial insurance coverage (50%+ of revenue) can decline if unemployment rises and patients shift to Medicaid (lower reimbursement rates). Elective admissions for eating disorders or less acute conditions show modest cyclicality. Overall, the defensive healthcare characteristics provide downside protection, but payer mix deterioration in recessions pressures margins.
Rising rates increase debt service costs on the company's $1.8-2.0B debt load (estimated based on 1.36x debt/equity ratio), directly pressuring free cash flow. Higher rates also compress valuation multiples for healthcare services stocks, as investors rotate toward bonds. Conversely, the company benefits from floating-rate asset yields on working capital. The negative FCF position (-$400M TTM) and ongoing capex needs ($600M annually for facility maintenance and growth) make refinancing risk material if rates remain elevated through 2026-2027 debt maturities.
Moderate - While not a lender, Acadia's access to capital markets for growth and refinancing is critical given negative FCF and high capex intensity. Credit spread widening increases borrowing costs and can constrain M&A activity. The company's BB credit profile (estimated, high-yield territory) makes it sensitive to high-yield market conditions. Additionally, financial stress among commercial insurers could lead to reimbursement disputes or payment delays, though this risk is diversified across hundreds of payers.
value/turnaround - The stock trades at 0.7x P/S and 1.2x P/B with negative earnings, attracting deep value investors betting on operational turnaround, margin recovery from labor cost normalization, and resolution of regulatory overhangs. The 65.6% 3-month return suggests momentum/event-driven interest, possibly from settlement of legal issues or improved operational metrics. Not suitable for income investors (no dividend) or growth-at-any-price buyers given negative FCF and modest 5% revenue growth.
high - Behavioral health stocks exhibit elevated volatility due to binary regulatory events (investigations, license suspensions), quarterly earnings surprises from labor cost swings, and M&A speculation. The -16.2% 1-year return followed by 65.6% 3-month surge demonstrates extreme sentiment shifts. Estimated beta of 1.3-1.5x based on sector comparables and operational leverage.
